A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment
NCT05624944
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
84
Enrollment
INDUSTRY
Sponsor class
Conditions
Patients with Mild or Moderate Hepatic Impairment
Interventions
DRUG:
TS-142 5 mg
Sponsor
Taisho Pharmaceutical Co., Ltd.